Printer Friendly

CORTECH FILLS SENIOR POSITIONS

 DENVER, Feb. 25 /PRNewswire/ -- Cortech Inc. (NASDAQ: CRTQ) has added two vice presidents, filled a position on its board and approved a scientific sabbatical for one of its founders, announced David K. Crossen, president and chief executive officer, today.
 Joining the biopharmaceutical company's senior management team are Kenneth R. Lynn, as vice president, Business Development and General Counsel, and Bernard L. Daina, Ph.D., vice president of Human Resources.
 Lynn joins Cortech from U.S. Bioscience Inc. (AMEX: UBS), a Pennsylvania pharmaceutical company, where he was vice president, General Counsel and Corporate Secretary. He also served as staff counsel to Marion Merrell Dow for seven years. Lynn earned his law degree from the University of Kansas in 1981 and his Master's of Business Administration through the Rockhurst College Executive Fellows Program in 1990.
 Daina, a management and organizational psychologist, joins the firm from his private consulting practice based in Denver. He has nine years' experience consulting to senior management in entrepreneurial technology firms. Daina previously held management positions in the private health care sector and in government. He earned his Doctorate in Clinical Psychology from Howard University in 1980.
 Crossen also announced that Jacqueline K. Barton, Ph.D., has joined the company's board of directors. Barton is a Professor of Chemistry at the California Institute of Technology, where she has taught and carried out research in bioinorganic chemistry since 1989. Previously she was a member of the faculty of the Departments of Chemistry and Biological Sciences at Columbia University, where she earned her Doctorate in Inorganic Chemistry in 1978. Barton, who is a MacArthur Foundation Fellow, a recipient of many awards from the American Chemical Society and a member of numerous scientific committees, also serves as a member of Dow Chemical's board of directors.
 Barton fills the Cortech board vacancy created when Philip S. Schein, M.D., chairman and chief executive officer of U.S. Bioscience resigned in October.
 Lastly, John C. Cheronis, Ph.D., M.D., a Cortech founder and chief scientific officer, will begin a 16-month scientific sabbatical in May. Cheronis will be conducting Cortech-related research at the University of Munich, Department of Clinical Biochemistry in Munich, Germany. He will work with Dr. Hans Fritz, a member of Cortech's scientific advisory board and an expert in the pathobiology of inflammation. Although Cheronis will step down as a company vice president during the sabbatical, he will remain on the board of directors.
 "Dr. Cheronis will now be in a position to conduct specific research on our behalf and to broaden his contributions to Cortech by working among some of the finest inflammation researchers in Europe," Crossen said. "We are all extremely pleased with this new relationship."
 Cortech is a Denver-based biopharmaceutical company focused on the design and development of two novel classes of drugs, bradykinin antagonists and neutrophil elastase inhibitors, to treat a broad range of inflammatory disorders. In addition, Cortech is developing a proprietary potential treatment for allergies and autoimmune diseases. Although Phase II trials for the company's lead bradykinin antagonist have begun, no assurance can be given that the company's therapeutic approaches will lead to successful product launches and product revenues. Cortech common stock is listed as CRTQ on NASDAQ.
 -0- 2/25/93
 /CONTACT: David K. Crossen or Joseph L. Turner of Cortech, 303-650-1200/
 (CRTQ UBS)


CO: Cortech Inc. ST: Colorado IN: MTC SU: PER

MC-BB -- DV001 -- 0221 02/25/93 08:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1993
Words:568
Previous Article:UNIVERSAL CORPORATION FILES REGISTRATION STATEMENT FOR PUBLIC OFFERING
Next Article:PACIFIC SCIENTIFIC ANNOUNCES DIVIDEND
Topics:


Related Articles
CORTECH ANNOUNCES INITIAL PUBLIC OFFERING
CORTECH CONVERSION RIGHTS EXPIRE
/C O R R E C T I O N -- CORTECH/
CORTECH ANNOUNCES 1992 FINANCIAL RESULTS
CORTECH AMPLIFIES ITS 1992 FINANCIAL RELEASE
CORTECH ELECTS NEW BOARD MEMBER
CORTECH PRESIDENT ANNOUNCES RESIGNATION
CORTECH APPOINTS KENNETH R. LYNN PRESIDENT AND CEO
CORTECH AND ONO COLLABORATE IN ORALELASTASE INHIBITOR DEVELOPMENT
ALLEN MISHER JOINS ORAVAX BOARD OF DIRECTORS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters